GlassScriptPhysician profile
Erika Negro
NPI 1194447730
$2,714.04
in general payments reported to CMS, 2019-2025
25 companies · $733 in 2025
The $733 reported for 2025 was more than what 78% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $337 · 2023: $909 · 2024: $735 · 2025: $733.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,278 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,277.84 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $336.98 | 2022-2025 | Briviact, Fintepla |
| Abbvie INC. | $307.81 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $228.61 | 2024-2025 | Acthar |
| Jazz Pharmaceuticals INC. | $220.60 | 2023-2025 | |
| Boston Scientific Corporation | $170.08 | 2023 | Watchman Flx |
| Otsuka America Pharmaceutical, INC. | $166.66 | 2023-2024 | Rexulti |
| Eisai INC. | $155.74 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $128.09 | 2025 | |
| Idorsia Pharmaceuticals US INC | $121.84 | 2022 | |
| Livanova USA, INC. | $109.12 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Teva Pharmaceuticals USA, INC. | $104.97 | 2022-2024 | Austedo Xr |
| Neurocrine Biosciences, INC. | $89.47 | 2022-2025 | Ingrezza |
| Lilly USA, LLC | $87.75 | 2023-2025 | Amyvid, Kisunla, Zepbound |
| Tg Therapeutics, INC. | $86.16 | 2023-2024 | |
| Lundbeck LLC | $85.60 | 2024 | Vyepti |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $76.28 | 2024-2025 | |
| Biogen, INC. | $48.88 | 2024-2025 | Tysabri, Vumerity, Plegridy |
| Takeda Pharmaceuticals U.S.A., INC. | $31.40 | 2024 | Hyqvia |
| Vanda Pharmaceuticals INC. | $28.50 | 2025 | Ponvory |
| Merz Pharmaceuticals, LLC | $27.88 | 2025 | Xeomin |
| Genentech USA, INC. | $27.06 | 2025 | Ocrevus Zunovo |
| Neurelis, INC. | $20.49 | 2025 | Valtoco |
| Astrazeneca Pharmaceuticals LP | $18.97 | 2024 | Wainua |
| Microtransponder, INC. | $18.26 | 2025 | |
| Aprecia Pharmaceuticals, LLC | $16.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erika Negro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.